N/A N=684 INtervention Study In overweiGHT Patients With COPD
Pulmonary Disease, Chronic Obstructive · Obesity · Weight Loss
Primary: Six Minute Walk Test — 1071.0; 1005.9 feet — p=.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=199 A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
Psoriasis
Primary: Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 — -1.07; -2.25; -2.47; -2.27 score on a scale — p=0.0041
Phase 2 N=292 An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Prostate Cancer
Primary: Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3) — 10.3; 15.4; 40.0; 11.1 Percentage of participants
Phase 2 N=250 A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
Acute Pain
Primary: Time-weighted Sum of the Pain Intensity Difference as Recorded on Numeric Pain Rating Scale (NPRS) 0 to 24 Hours (SPID24) After First Dose — 19.1; 37.3; 32.3; 30.5 units…
Phase 2 N=22 Carbidopa for the Treatment of Excessive Blood Pressure Variability
Dysautonomia, Familial · Baroreflex Failure Syndrome
Primary: Number of Participants Who Reported Adverse Events Related to Study Drug — 0; 0; 0 Participants
Phase 2 N=66 Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Vosaroxin in Combination With Decitabine — 70 Mg/m^2
Phase 2 N=134 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants
N/A N=90 Stress Reduction Study for Partners of Early Stage Dementia
Dementia Caregiving
Primary: Change in Perceived Stress — 13.6; 17.8 score on a scale — p=<.05
N/A N=68 Developing a Dyadic Intervention for Sexually Transmitted Infection (STI)/HIV Prevention in Youth
Exposure to Sexually Transmissible Disorder (Event)
Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants
Phase 2 N=1,924 Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 476; 496; 506; 1002 Participants
Phase 3 N=167 An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Generalized Myasthenia Gravis
Primary: Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population — 67.7; 29.7 percentage of patients — p=<0.0001
Phase 2 N=2,699 Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 812; 794; 805; 1599 Participants
Phase 1 N=12 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Neoplasms With Mesothelin Expression · Epithelioid Mesothelioma · Cholangiocarcinoma, Extrahepatic
Primary: Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib — 100 mcg/kg given days 4, 6, 8 every cycle
N/A N=33 Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients
Respiration, Artificial · Critical Illness · Chronic Disease
Primary: Functional Assessment: Handgrip — 3.6; 1.3 kg
Phase 2 N=25 Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Psoriasis
Primary: Number of Treatment of Emergent Adverse Events — 2; 4; 2; 1 Participants